Table 2.

Patient characteristics and disease response in patients treated preemptively with TAA-T infusion.

Patient IDAge/sexDiagnosis and high-risk featuresDonor and transplant typePosttransplant treatmentDay post-BMT at time of TAA-T infusionTAA-T dose level (number of doses)ALC at first infusion (k/IU)Best response postinfusionTime to relapse postinfusion (days)Survival postinfusion (days)
12 9 Years/F AML MLL, NPM1 HLA = sibling NMA Azacitidine maintenance +189 4 (1) 0.52 CCR 134 728 
13 31 Years/M AML MLL t11:16 t7:11 der7 partial trisomy 11q ATM and WT1 mutation HLA = sibling MA None +337 4 (1) 1.82 CCR N/A 806+ 
14 67 Years/F AML/MDS MiniHaplo NMA None +167 1 (1) 3.27 CCR N/A 561+ 
15 31 Years/M AML NPM1, PTPN1 mutation HLA = sibling NMA None +261 2 (1) 0.98 CCR N/A 368+ 
16 25 Years/M AML FLT3 HLA = sibling MA Gilteritinib +212 4 (1) 1.30 CCR N/A 383+ 
17 1 Years/F AML MLL rearrangement Haplo MA None +131 4 (1) 4.09 CCR N/A 771+ 
18 59 Years/M AML monosomy 7 Haplo MA None +92 4 (1) 0.51 CCR 700 707+ 
19 47 Years/F AML TP53 complex karyotype Haplo NMA None +149 4 (1) 0.64 PD (MRD+ day 35) 275 644 
20 7 Years/F AML inv(16) HLA = sibling MA None +55 4 (1) 1.30 CCR N/A 380+ 
21 28 Years/F AML leukemia cutis Haplo NMA None +148 4 (1) 2.20 CCR 64 228 
22 18 Years/F AML GATA2, germline mutation Haplo NMA None +83 3 (1) 1.10 CCR 126 126+ 
23 23 Years/M AML relapsed pretransplant HLA = sibling RI None +148 4 (1) 0.57 CCR N/A 189+ 
Patient IDAge/sexDiagnosis and high-risk featuresDonor and transplant typePosttransplant treatmentDay post-BMT at time of TAA-T infusionTAA-T dose level (number of doses)ALC at first infusion (k/IU)Best response postinfusionTime to relapse postinfusion (days)Survival postinfusion (days)
12 9 Years/F AML MLL, NPM1 HLA = sibling NMA Azacitidine maintenance +189 4 (1) 0.52 CCR 134 728 
13 31 Years/M AML MLL t11:16 t7:11 der7 partial trisomy 11q ATM and WT1 mutation HLA = sibling MA None +337 4 (1) 1.82 CCR N/A 806+ 
14 67 Years/F AML/MDS MiniHaplo NMA None +167 1 (1) 3.27 CCR N/A 561+ 
15 31 Years/M AML NPM1, PTPN1 mutation HLA = sibling NMA None +261 2 (1) 0.98 CCR N/A 368+ 
16 25 Years/M AML FLT3 HLA = sibling MA Gilteritinib +212 4 (1) 1.30 CCR N/A 383+ 
17 1 Years/F AML MLL rearrangement Haplo MA None +131 4 (1) 4.09 CCR N/A 771+ 
18 59 Years/M AML monosomy 7 Haplo MA None +92 4 (1) 0.51 CCR 700 707+ 
19 47 Years/F AML TP53 complex karyotype Haplo NMA None +149 4 (1) 0.64 PD (MRD+ day 35) 275 644 
20 7 Years/F AML inv(16) HLA = sibling MA None +55 4 (1) 1.30 CCR N/A 380+ 
21 28 Years/F AML leukemia cutis Haplo NMA None +148 4 (1) 2.20 CCR 64 228 
22 18 Years/F AML GATA2, germline mutation Haplo NMA None +83 3 (1) 1.10 CCR 126 126+ 
23 23 Years/M AML relapsed pretransplant HLA = sibling RI None +148 4 (1) 0.57 CCR N/A 189+ 

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Haplo, haploidentical donor; HLA = sibling, HLA-matched sibling; MA, myeloablative BMT; MDS, myelodysplastic syndrome; NMA, nonmyeloablative BMT; PD, progressive disease; RI, reduced intensity BMT.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal